37. B hm M, Robertson M, Ford I, et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol. 2015;116:1890 7. 38. Swedberg K, Komajda M, B hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875 85. 39. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091 9. 40. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807 16. Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure (December 2015) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Voting Recusals By Section* Clyde W. Yancy, Chair Northwestern University Feinberg School of Medicine, Division of Cardiology Professor of Medicine and Chief; Diversity and Inclusion Vice Dean None None None None None None None Mariell Jessup, Vice Chair University of Pennsylvania Professor of Medicine None None None None None None None Biykem Bozkurt Michael E. DeBakey VA Medical Center The Mary and Gordon Cain Chair and Professor of Medicine None None None Novartis None None 7.3.2.10 and 7.3.2.11. (Continued) Yancy et al Javed Butler Stony Brook University Division Chief of Cardiology Bayer CardioCell Medtronic Merck Novartis Relypsa Takeda Trevena Z Pharma Zensun Novartis None Amgen (DSMB) None None 7.3.2.10 and 7.3.2.11. 